Drug Profile
SP 160412
Alternative Names: SP160412Latest Information Update: 17 Mar 2021
Price :
$50
*
At a glance
- Originator Sephoris Pharmaceuticals
- Class Antiallergics; Antihistamines; Nonsteroidal anti-inflammatories; Phenylpropionates; Sedating antihistamines
- Mechanism of Action Cyclooxygenase inhibitors; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Photodamage
Most Recent Events
- 17 Mar 2021 Discontinued - Phase-II for Photodamage in USA (PO)
- 25 Sep 2019 Sephoris Pharmaceuticals terminates a phase II trial in Photodamage in USA for lack of efficacy (PO) (NCT03332524)
- 15 Jan 2018 Phase-II clinical trials in Photodamage in USA (PO) (NCT03332524)